Search - tctmd.com

Displaying 21 - 40 of 46

Sort: Relevancy | Date

News Daily News

Little Improvement Seen Over Two Decades in US Racial Health Disparities

L.A. McKeown

March 15, 2021

News Daily News

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Michael O'Riordan

May 13, 2019

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Shelley Wood

November 23, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

‘Doomed’ by Genetics? Lifestyle Still Matters in Preventing CVD and Diabetes

Yael L. Maxwell

June 29, 2018

News Daily News

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Yael L. Maxwell

January 09, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

螯合治疗：TACT2 试验为糖尿病传统 MI 后治疗提供前景

Shelley Wood

September 28, 2016

News Daily News

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Shelley Wood

September 28, 2016

News Daily News

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Michael O'Riordan

September 13, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Don’t Dismiss Diabetes: Long-Term Mortality After Acute MI Linked With the Disease in Large Population Study

Yael L. Maxwell

June 29, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

L.A. McKeown

May 26, 2016

News Daily News

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Yael L. Maxwell

May 13, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

Advertisement

Little Improvement Seen Over Two Decades in US Racial Health Disparities

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

‘Doomed’ by Genetics? Lifestyle Still Matters in Preventing CVD and Diabetes

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

TCTMD’s Top 10 Most Popular Stories for December 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

螯合治疗：TACT2 试验为糖尿病传统 MI 后治疗提供前景

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Don’t Dismiss Diabetes: Long-Term Mortality After Acute MI Linked With the Disease in Large Population Study

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content